IgGenix

United Statesiggenix.com
aliveseries-c-plus
series-c-plus
Stage
1
Investors

About

IgGenix is a biotechnology company that discovers and engineers allergen-specific antibodies to block and prevent allergic reactions, aiming to treat pediatric and adult patients with severe allergies.

Explore IgGenix's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.